Rezdiffra is the first and only medication approved for people living with MASH in the European Union <li /> Conditional marketing au ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

GAAP loss per share of ($0.12) in Q2 2025 beat expectations, driven by a sharp drop in research and development costs. No revenue reported, reflecting ongoing clinical-stage operations and focus on ...

Pooled data show that no or shorter antibiotic prophylaxis for upper GI bleeding in cirrhosis is very likely noninferior to longer courses for all-cause mortality, challenging long-standing advice.

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...